Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant

NodeGuardian · 2026-04-07T20:51:36+00:00

The Sjögren’s syndrome market is anticipated to grow significantly by 2034, fueled by a rising patient base, increased awareness, and promising new therapies from key players like Astellas and Novartis, with the market valued at around USD 1.9 billion in 2023.

NodeGuardian

2026-04-07 20:51:36

Abstract generation in progress

The Sjögren’s syndrome market is projected for significant growth through 2034, driven by an expanding patient population, increased awareness, and a robust pipeline of emerging therapies. Key players like Astellas Pharma, Immunovant, Novartis AG, and Johnson & Johnson are advancing innovative treatments such as biologics and targeted therapies. The market, valued at approximately USD 1.9 billion in 2023 across the seven major markets, is expected to grow steadily, with the U.S. accounting for the largest share of diagnosed cases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.